| Neural correlates of the DMT experience assessed with multivariate EEG C Timmermann, L Roseman, M Schartner, R Milliere, LTJ Williams, ... Scientific reports 9 (1), 16324, 2019 | 373 | 2019 |
| High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe C Nyakutira, D Röshammar, E Chigutsa, P Chonzi, M Ashton, C Nhachi, ... European journal of clinical pharmacology 64 (4), 357-365, 2008 | 250 | 2008 |
| Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin Svensson, Ashton British journal of clinical pharmacology 48 (4), 528-535, 1999 | 243 | 1999 |
| Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults M Ashton, TN Hai, ND Sy, DX Huong, N Van Huong, NT Nieu, LD Công Drug Metabolism and Disposition 26 (1), 25-27, 1998 | 164 | 1998 |
| Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand J Tarning, EA Ashley, N Lindegardh, K Stepniewska, L Phaiphun, ... Antimicrobial agents and chemotherapy 52 (3), 1052-1061, 2008 | 157 | 2008 |
| Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients MH Alin, M Ashton, CM Kihamia, GJB Mtey, A Björkman Transactions of the Royal Society of Tropical Medicine and Hygiene 90 (1), 61-65, 1996 | 157 | 1996 |
| Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria M Ashton, ND Sy, N Van Huong, T Gordi, TN Hai, DX Huong, NT Niêu, ... Clinical Pharmacology & Therapeutics 63 (4), 482-493, 1998 | 153 | 1998 |
| A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first‐pass hepatic extraction T Gordi, R Xie, NV Huong, DX Huong, MO Karlsson, M Ashton British journal of clinical pharmacology 59 (2), 189-198, 2005 | 129 | 2005 |
| Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9 USH Simonsson, B Jansson, TN Hai, DX Huong, G Tybring, M Ashton Clinical Pharmacology & Therapeutics 74 (1), 32-43, 2003 | 127 | 2003 |
| Artemisinin induces omeprazole metabolism in human beings USH Svensson, M Ashton, TN Hai, L Bertilsson, DX Huong, N Van Huong, ... Clinical Pharmacology & Therapeutics 64 (2), 160-167, 1998 | 104 | 1998 |
| Pitfalls in estimating piperaquine elimination J Tarning, N Lindegårdh, A Annerberg, T Singtoroj, NPJ Day, M Ashton, ... Antimicrobial agents and chemotherapy 49 (12), 5127-5128, 2005 | 95 | 2005 |
| Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens T Gordi, DX Huong, TN Hai, NT Nieu, M Ashton Antimicrobial agents and chemotherapy 46 (4), 1026-1031, 2002 | 95 | 2002 |
| Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects S Asimus, D Elsherbiny, TN Hai, B Jansson, NV Huong, MG Petzold, ... Fundamental & clinical pharmacology 21 (3), 307-316, 2007 | 94 | 2007 |
| A new approach to evaluate regression models during validation of bioanalytical assays T Singtoroj, J Tarning, A Annerberg, M Ashton, Y Bergqvist, NJ White, ... Journal of Pharmaceutical and Biomedical Analysis 41 (1), 219-227, 2006 | 94 | 2006 |
| Artemisinin pharmacokinetics in healthy adults after 250, 500 and 1000 mg single oral doses M Ashton, T Gordi, TN Hai, N Van Huong, ND Sy, NT Nieu, DX Huong, ... Biopharmaceutics & drug disposition 19 (4), 245-250, 1998 | 88 | 1998 |
| Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria M Hassan Alin, M Ashton, CM Kihamia, GJB Mtey, A Björkman British Journal of Clinical Pharmacology 41 (6), 587-592, 1996 | 86 | 1996 |
| High in situ rat intestinal permeability of artemisinin unaffected by multiple dosing and with no evidence of P-glycoprotein involvement USH Svensson, R Sandström, Ö Carlborg, H Lennernäs, M Ashton Drug metabolism and disposition 27 (2), 227-232, 1999 | 84 | 1999 |
| Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study AJ Weinberg, DH Zappe, M Ashton, MS Weinberg American journal of nephrology 24 (3), 340-345, 2004 | 81 | 2004 |
| Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam MI Veiga, S Asimus, PE Ferreira, JP Martins, I Cavaco, V Ribeiro, TN Hai, ... European journal of clinical pharmacology 65 (4), 355-363, 2009 | 77 | 2009 |
| Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria US Svensson, M Alin, MO Karlsson, Y Bergqvist, M Ashton European journal of clinical pharmacology 58 (5), 339-351, 2002 | 69 | 2002 |
